NCT03110549 is a Phase 1 clinical trial of TMB-607 in Human Immunodeficiency Virus, sponsored by TaiMed Biologics Inc..

Who is sponsoring NCT03110549?

NCT03110549 is sponsored by TaiMed Biologics Inc..

What drugs are being tested in NCT03110549?

Interventions in NCT03110549: TMB-607, Placebo.

What condition does NCT03110549 study?

NCT03110549 studies Human Immunodeficiency Virus.

Is NCT03110549 still recruiting?

NCT03110549 is currently terminated. Last updated 12 May 2020.

Last reviewed 2020-05-12 · How we verify

NCT03110549

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

Terminated Phase 1 Last updated 12 May 2020

What this trial tests

Phase 1 trial testing TMB-607 in Human Immunodeficiency Virus in 9 participants. Terminated before completion.

Timeline

21 November 2016

Primary endpoint
22 July 2019

22 July 2019

Quick facts

Lead sponsor	TaiMed Biologics Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	triple
Primary purpose	treatment
Enrollment	9
Start date	21 November 2016
Primary completion	22 July 2019
Estimated completion	22 July 2019
Sites	1 location across United States

Drugs / interventions tested

TMB-607 — full drug profile →
Placebo

Conditions studied

Human Immunodeficiency Virus — all drugs for Human Immunodeficiency Virus →

Sponsor

TaiMed Biologics Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Human Immunodeficiency Virus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative volunteers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond.
Chaudhuri S, Symons JA, Deval J. · · 2018 · cited 136× · PMID 29758235 · DOI 10.1016/j.antiviral.2018.05.005
Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I, Sivanandam M, Kumaradhas P. · · 2021 · cited 19× · PMID 32627689 · DOI 10.1080/07391102.2020.1786459

Verify or expand the search:

Other recruiting trials for Human Immunodeficiency Virus

Currently open trials in the same condition.

NCT07530198 — HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong · Phase 1 · recruiting
NCT06819176 — Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretrovir · Phase 1 · recruiting
NCT06408142 — Universal Test and Connect for HIV Service Delivery in South Africa · recruiting
NCT07101458 — The Eswatini PRISM Study on Adolescents Living With HIV · NA · recruiting
NCT06554223 — The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care · NA · recruiting

Other TaiMed Biologics Inc. trials

Trials by the same sponsor.

NCT05275998 — TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals · Phase 1, PHASE2 · completed
NCT04027387 — Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants · Phase 1 · completed
NCT03913195 — Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03110549 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TaiMed Biologics Inc.
Last refreshed: 12 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03110549.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing